Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders

Core Insights - Jaguar Health, Inc. is presenting updates on near-term catalysts at the Emerging Growth Conference on December 10, 2025 [1] - Initial results from an ongoing proof-of-concept trial indicate that crofelemer may extend the lives of infants with intestinal failure due to microvillus inclusion disease (MVID) by reducing the necessary total parenteral support (PS) volume, with a significant PS reduction of up to 37% [1] - There are currently no approved treatments for MVID, highlighting the potential market opportunity for crofelemer [1] - The company completed a meeting with the FDA on October 2, 2025, to discuss advancing its placebo-controlled trial of crofelemer, aiming for a possible expedited approval pathway for MVID treatment [1] - The company held a Special Meeting of Stockholders on December 8, 2025, where three proposals were submitted and approved [1]